GlassScriptPhysician profile
Joseph Nissenfeld
NPI 1497956668
$2,864.69
in general payments reported to CMS, 2019-2025
17 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $48.17 · 2021: $304 · 2022: $805 · 2023: $694 · 2024: $444 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $756.45 | 2021-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $570.73 | 2021-2025 | |
| Alkermes, INC. | $336.25 | 2020-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $255.04 | 2022-2025 | Sublocade, Perseris |
| Otsuka America Pharmaceutical, INC. | $213.17 | 2020-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $127.36 | 2022-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.85 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $99.11 | 2022-2023 | Ingrezza |
| Axsome Therapeutics, INC. | $88.28 | 2022-2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $78.10 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $65.08 | 2023-2024 | Loreev Xr, Gralise |
| Supernus Pharmaceuticals, INC. | $39.58 | 2023-2025 | Qelbree, Qelbree |
| Luye Pharma (USA) LTD. | $31.14 | 2025 | Erzofri Extended-Release |
| Sunovion Pharmaceuticals INC. | $27.89 | 2022 | |
| Biogen, INC. | $26.07 | 2024 | Zurzuvae |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $23.92 | 2023 | Aplenzin |
| Lundbeck LLC | $21.67 | 2023 | Abilify Maintena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Nissenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.